StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
37
Publishing Date
2023 - 09 - 12
1
2023 - 09 - 07
1
2023 - 07 - 05
1
2023 - 06 - 26
1
2023 - 05 - 04
1
2023 - 02 - 15
1
2023 - 02 - 12
1
2022 - 11 - 29
1
2022 - 10 - 17
1
2022 - 10 - 06
1
2022 - 09 - 26
1
2022 - 08 - 31
2
2022 - 08 - 03
1
2022 - 06 - 14
1
2022 - 06 - 03
1
2022 - 05 - 17
1
2022 - 03 - 31
1
2021 - 12 - 07
1
2021 - 12 - 05
1
2021 - 11 - 12
1
2021 - 11 - 01
1
2021 - 10 - 27
2
2021 - 09 - 02
1
2021 - 07 - 23
1
2021 - 07 - 06
1
2021 - 06 - 04
1
2021 - 04 - 20
1
2021 - 03 - 25
1
2021 - 03 - 08
1
2021 - 03 - 02
2
2021 - 03 - 01
1
2021 - 02 - 09
1
2021 - 01 - 27
1
2021 - 01 - 26
1
Sector
Communications
1
Health technology
37
Tags
Agreement
6
Antibody
23
Approval
6
Authorized
7
Back
4
Biotech-beach
19
Brazil
6
Cancer
17
Ceo
6
China
4
Clearance
13
Clinical-trials-phase-ii
7
Commercialization
5
Company
10
Conference
14
Covid
35
Covid-19
16
Diagnostic
4
Distribution
4
Drop
6
Drug
11
Drug delivery
4
Enroll
7
Fda
21
Fda clearance
8
Financial
4
Infections
4
License
14
Liver
4
Market
6
Meeting
5
N/a
183
Opioid
5
Order
4
Osteoarthritis
4
Pharmaceuticals
6
Phase 1
10
Phase 1b
6
Phase 2
20
Phase 2b
8
Phase 3
8
Positive
19
Research
8
Results
28
Sars-cov-2
17
Solid tumors
4
Sp-102
4
Sp-103
5
Sti-1558
8
Sti-9167
4
Study
9
T-cell
4
Test
13
Therapeutics
22
Therapy
9
Treatment
37
Trial
33
Vaccine
8
Virpax
5
Ztlido
8
Entities
Orange
1
Scilex holding company
2
Sorrento therapeutics, inc.
37
Teva pharmaceutical industries limited
1
Symbols
ABBV
117
ABT
57
ADMP
19
ALNY
38
ALPMF
50
ALPMY
50
AMGN
46
ARQT
24
ARWR
21
AZN
46
AZNCF
38
BHC
35
BIIB
41
BMY
93
BSX
21
BTAI
19
BWAY
39
CHRS
28
CNSP
26
ECL
47
FBIO
27
FNCTF
84
GILD
50
GLAXF
73
GSK
98
HOTH
24
HZNP
19
INCY
77
IONS
19
JNJ
198
KPTI
27
LLY
175
MBRX
28
MDT
44
MMM
20
MNOV
24
MRK
63
NRXP
19
NTLA
31
NVO
34
NVS
137
NVSEF
113
PFE
74
PHG
20
PRGO
19
RARE
25
REGN
57
RETA
28
RGNX
25
SNY
279
SNYNF
231
SRNE
37
TAK
50
TEVJF
76
TGTX
24
TNXP
29
VRCA
23
VRTX
27
VTRS
45
XYL
35
Exchanges
Nasdaq
37
Nyse
1
Crawled Date
2023 - 09 - 12
1
2023 - 09 - 07
1
2023 - 07 - 05
1
2023 - 06 - 26
1
2023 - 05 - 04
1
2023 - 02 - 15
1
2023 - 02 - 13
1
2022 - 11 - 29
1
2022 - 10 - 17
1
2022 - 10 - 06
1
2022 - 09 - 26
1
2022 - 08 - 31
2
2022 - 08 - 03
1
2022 - 06 - 14
1
2022 - 06 - 03
1
2022 - 05 - 17
1
2022 - 03 - 31
1
2021 - 12 - 07
1
2021 - 12 - 05
1
2021 - 11 - 12
1
2021 - 11 - 01
1
2021 - 10 - 27
2
2021 - 09 - 02
1
2021 - 07 - 23
1
2021 - 07 - 06
1
2021 - 06 - 04
1
2021 - 04 - 20
1
2021 - 03 - 25
1
2021 - 03 - 08
1
2021 - 03 - 02
2
2021 - 03 - 01
1
2021 - 02 - 09
1
2021 - 01 - 27
2
Crawled Time
00:00
1
01:00
2
04:00
2
08:00
1
13:00
4
13:20
3
13:30
1
14:00
4
14:04
2
15:00
2
15:20
2
16:00
3
18:00
2
19:00
3
20:00
2
20:20
1
21:00
1
21:04
1
Source
www.biospace.com
8
www.globenewswire.com
28
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Treatment
symbols :
SRNE
save search
Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19
Published:
2023-09-12
(Crawled : 13:30)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-95.24%
|
O:
-3.62%
H:
7.95%
C:
-8.1%
covid-19
treatment
trial
Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) for the Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Published:
2023-09-07
(Crawled : 13:00)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-93.49%
|
O:
0.52%
H:
42.58%
C:
36.03%
osteoarthritis
positive
treatment
trial
therapeutics
results
Sorrento Announces Positive Phase IIa Study Results of Abivertinib for the Treatment of Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) and Its Plan for a Pivotal Phase III Study
Published:
2023-07-05
(Crawled : 13:00)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-97.17%
|
O:
5.1%
H:
1.02%
C:
-0.27%
positive
treatment
results
study
Sorrento Announces the Full Enrollment of the Pivotal Phase 3 Trial with Olgotrelvir (OVYDSOTM) (STI-1558), a Second Generation Oral Mpro Inhibitor, as a Standalone Treatment for COVID-19
Published:
2023-06-26
(Crawled : 13:20)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-97.11%
|
O:
3.9%
H:
0.0%
C:
-3.06%
sti-1558
covid-19
treatment
trial
Scilex Holding Company Announces Complete Enrollment of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 (lidocaine topical system) 5.4%, Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain
Published:
2023-05-04
(Crawled : 13:00)
- globenewswire.com
SCLX
|
$0.984
3.43%
3.31%
550K
|
|
-82.73%
|
O:
0.0%
H:
4.91%
C:
-4.36%
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-95.85%
|
O:
-0.46%
H:
2.92%
C:
-0.5%
sp-103
ztlido
back
treatment
study
Sciatica Treatment Market to Reach USD 991.3 Million, Globally, by 2031 at 3.9% CAGR: Allied Market Research
Published:
2023-02-15
(Crawled : 16:00)
- prnewswire.com
TEVA
|
$13.01
1.01%
0.0%
8.9M
|
Health Technology
|
25.66%
|
O:
-0.98%
H:
1.58%
C:
1.58%
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-94.94%
|
O:
1.27%
H:
2.75%
C:
-17.4%
treatment
research
market
Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine
Published:
2023-02-12
(Crawled : 00:00)
- globenewswire.com
SCLX
|
$0.984
3.43%
3.31%
550K
|
|
-90.11%
|
O:
-20.92%
H:
10.39%
C:
-6.84%
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-98.94%
|
O:
-35.61%
H:
9.04%
C:
-57.51%
treatment
canada
migraine
Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
Published:
2022-11-29
(Crawled : 20:00)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.2%
|
O:
1.6%
H:
3.54%
C:
2.36%
sti-1558
covid-19
treatment
australia
topline
china
positive
study
Sorrento Successfully Completes Phase 1 Study and Is Proceeding to Implement Global Registrational Trials with STI-1558, an Oral Mpro Inhibitor as a Standalone Oral Treatment and Prevention of COVID-19 without the Need for a Ritonavir Booster
Published:
2022-10-17
(Crawled : 13:00)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.25%
|
O:
4.48%
H:
11.43%
C:
9.29%
sti-1558
covid-19
treatment
trials
global
study
Sorrento Therapeutics to Participate in Key Opinion Leader Panel Discussion on “New Horizons for the Treatment of Non-small Cell Lung Cancer”
Published:
2022-10-06
(Crawled : 13:20)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.38%
|
O:
-1.24%
H:
3.46%
C:
-1.89%
treatment
lung
therapeutics
Sorrento Therapeutics Completes Enrollment of Phase 2 Clinical Trial of Resiniferatoxin (RTX) for Treatment of Knee Pain in Moderate to Severe Osteoarthritis of the Knee (OAK) Patients
Published:
2022-09-26
(Crawled : 14:00)
- biospace.com/
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.35%
|
O:
-0.65%
H:
5.19%
C:
-1.95%
treatment
osteoarthritis
trial
therapeutics
phase 2
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute LBP
Published:
2022-08-31
(Crawled : 08:00)
- biospace.com/
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.48%
|
O:
5.15%
H:
2.94%
C:
0.49%
sp-103
ztlido
treatment
fda
designation
granted
fast track designation
Scilex Holding Company, a Sorrento Company, Announces That the FDA Has Granted Fast Track Designation for SP-103 (Lidocaine Topical System) 5.4%, Next Generation Triple Strength Formulation of ZTlido®, for the Treatment of Acute Low Back Pain (LBP)
Published:
2022-08-31
(Crawled : 04:00)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.48%
|
O:
5.15%
H:
2.94%
C:
0.49%
sp-103
ztlido
treatment
fda
designation
back
granted
fast track designation
Sorrento Completes Successfully the SAD Study and Initiates the MAD Phase 1 Study with STI-1558, An Oral M(pro) Inhibitor as a Standalone Treatment and Prevention of COVID-19 without the Ritonavir as Booster
Published:
2022-08-03
(Crawled : 13:20)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.61%
|
O:
0.77%
H:
8.32%
C:
2.3%
sti-1558
covid-19
treatment
study
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.
Published:
2022-06-14
(Crawled : 15:00)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.28%
|
O:
2.16%
H:
1.41%
C:
-0.7%
gloperba
treatment
license
Sorrento Therapeutics Announces First Subject Dosed in a Phase I Clinical Study of STI-1558, an Oral Mpro Inhibitor as a Standalone Treatment and Prevention of COVID-19 Without Co-Administration of Ritonavir Booster
Published:
2022-06-03
(Crawled : 15:20)
- biospace.com/
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.37%
|
O:
8.18%
H:
2.33%
C:
-0.58%
sti-1558
covid-19
treatment
therapeutics
Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
Published:
2022-05-17
(Crawled : 15:20)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.31%
|
O:
4.17%
H:
6.0%
C:
4.67%
treatment
license
trial
cancer
enroll
antibody
Sorrento Reports FDA Clearance for the Commencement of a Phase 2/3 Study for Abivertinib in Treatment of Hospitalized Patients With Severe Pneumonia Due to COVID-19
Published:
2022-03-31
(Crawled : 14:00)
- biospace.com/
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.58%
|
O:
1.27%
H:
0.26%
C:
-2.92%
covid-19
treatment
fda
clearance
phase 2
Sorrento Begins Enrollment in Phase 2 Trial of Resiniferatoxin (RTX) for the Treatment of Pain Due to Knee Osteoarthritis (OA)
Published:
2021-12-07
(Crawled : 19:00)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.83%
|
O:
-1.68%
H:
9.4%
C:
7.52%
treatment
phase 2
xin
osteoarthritis
trial
enroll
Sorrento Announces Publication of a Series of Novel SARS-CoV-2 Main Protease (MPRO) Inhibitors for Potential Treatment of COVID-19 Patients Infected With SARS-CoV-2 Variants Of Concern, Including Omicron
Published:
2021-12-05
(Crawled : 20:20)
- globenewswire.com
SRNE
|
$0.015
-8.85%
140K
|
Health Technology
|
-99.82%
|
O:
-9.22%
H:
0.0%
C:
0.0%
treatment
covid
potential
sars-cov-2
infections
← Previous
1
2
Next →
Gainers vs Losers
79%
21%
Top 10 Gainers
MTTR
|
News
M
|
$4.6
164.37%
62.17%
28M
|
AGBA
|
$2.94
135.2%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.46
71.81%
41.8%
2M
|
MTC
|
$2.25
44.23%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.175
41.11%
29.13%
12M
|
Finance
SHIM
|
$3.05
35.56%
26.23%
870K
|
HKIT
|
$1.345
31.86%
24.16%
390K
|
Technology Services
ABVC
|
$1.36
30.77%
23.53%
7.4M
|
Wholesale Trade
OST
|
$0.512
28.0%
21.88%
290K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.